Arnold M. Baskies Purchases 5,000 Shares of Anixa Biosciences, Inc. (NASDAQ:ANIX) Stock

Anixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) Director Arnold M. Baskies acquired 5,000 shares of the stock in a transaction dated Tuesday, January 28th. The stock was acquired at an average cost of $2.82 per share, for a total transaction of $14,100.00. Following the purchase, the director now directly owns 120,000 shares in the company, valued at approximately $338,400. The trade was a 4.35 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Anixa Biosciences Price Performance

Shares of ANIX opened at $3.00 on Thursday. Anixa Biosciences, Inc. has a one year low of $2.07 and a one year high of $4.70. The company has a 50-day moving average of $2.75 and a two-hundred day moving average of $3.05. The stock has a market cap of $96.60 million, a price-to-earnings ratio of -7.69 and a beta of 0.90.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last posted its quarterly earnings data on Friday, January 10th. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.02. Analysts anticipate that Anixa Biosciences, Inc. will post -0.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth




A number of brokerages recently weighed in on ANIX. D. Boral Capital restated a "buy" rating and set a $10.00 target price on shares of Anixa Biosciences in a report on Wednesday, January 22nd. HC Wainwright restated a "buy" rating and issued a $7.00 target price on shares of Anixa Biosciences in a report on Tuesday, November 19th.

Get Our Latest Research Report on ANIX

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Virtu Financial LLC acquired a new stake in Anixa Biosciences during the 3rd quarter worth about $34,000. Tyler Stone Wealth Management lifted its position in shares of Anixa Biosciences by 100.0% in the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company's stock worth $132,000 after purchasing an additional 21,008 shares in the last quarter. Westside Investment Management Inc. boosted its holdings in shares of Anixa Biosciences by 151.8% during the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company's stock worth $110,000 after purchasing an additional 21,100 shares during the period. Finally, International Assets Investment Management LLC grew its position in Anixa Biosciences by 170.0% during the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company's stock valued at $1,190,000 after purchasing an additional 23,800 shares in the last quarter. 29.13% of the stock is owned by institutional investors and hedge funds.

Anixa Biosciences Company Profile

(Get Free Report)

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.

Read More

Insider Buying and Selling by Quarter for Anixa Biosciences (NASDAQ:ANIX)

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.

Insider Buying or Selling at Anixa Biosciences?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Anixa Biosciences and related companies.
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles